Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin for Nocturia in Men (NOC)
NCT01694498Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2012
- Primary completion
- Jun 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of desmopressin in nocturia (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Change from baseline in mean number of nocturnal voids at 12 weeks. Started Sep 2012; status: completed.
02
Drugs
desmopressin
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT01694498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01694498.